These studies, however, helped to refine the understanding of MYB-NFIB fusion oncogene as a specific and common driver of ACC pathogenesis in multiple anatomical locations, including breast [15, 30], lacrimal glands [16] and skin [32, 33]. This evidence concerns the gene NFIB and adrenal cortex carcinoma.